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Abstract. Amodiaquine, a 4-aminoquinoline compound, is being considered as an alternative to chloroquine and
pyrimethamine/sulfadoxine where resistance in Plasmodium falciparum to both drugs has been selected. Although
amodiaquine is more potent than chloroquine, its effectiveness is reduced in areas where chloroquine resistance is high.
We report an association of the P. falciparum chloroquine resistance transporter (pfcrt) gene and the P. falciparum
multiple drug resistance 1 (pfmdr1) gene, two chloroquine resistance markers, with chloroquine and amodiaquine
efficacy in vivo in southern Sudan. The data show that the allele of the pfcrt gene with a lysine to threonine change at
codon 76 is strongly associated with both chloroquine and amodiaquine resistance. No such association was observed
with the pfmdr1 gene.
In response to the spread of resistance to chloroquine (CQ)
and pyrimethamine/sulfadoxine (Fansidar
®; F. Hoffmann-La
Roche, Basel, Switzerland), amodiaquine (AQ) is now being
considered as an alternative option for the management of
uncomplicated Plasmodium falciparum malaria in Africa.
1,2
Although this drug remains effective in areas of substantial
CQ resistance,
3−6 the two drugs are chemically related and
several clinical
1,2,7 and in vitro
8,9 reports have shown cross-
resistance between CQ and AQ or the active metabolite of AQ.
Many studies have been devoted to understanding the
mechanism of CQ resistance.
10. Point mutations in the P. fal-
ciparum chloroquine resistance transporter (pfcrt) gene and,
to a lesser extent, in the P. falciparum multiple drug resis-
tance 1 (pfmdr1) gene are associated with CQ resistance.
Polymorphism in the pfcrt gene has been reported to corre-
late with CQ resistance.
11,12 Among the amino acid changes
in this protein, the lysine to threonine change at position 76
(pfcrt 76T) is the most strongly associated with CQ resistance
both in vivo and in vitro.
11,12 Recently, transfection of the
pfcrt gene has clearly demonstrated the role of this mutant
allele in CQ resistance in vitro.
13,14 However, in semi-immune
populations, the value of this mutation for predicting clinical
outcomes after CQ treatment has not been consistent.
15,16
The point mutation of asparagine to tyrosine at codon 86 in
the pfmdr1 gene (pfmdr1 86Y) has been associated with CQ
resistance in some studies,
17,18 but not in others.
19,20
The molecular mechanisms of CQ and AQ cross-resistance
have not yet been addressed, but the similarity of their chemi-
cal structures, their likely common mode of action,
21,22 and
some apparent cross-resistance suggest that molecular mark-
ers selected as a function of CQ use might also compromise
effectiveness of AQ. We report the impact of mutant alleles
pfcrt76T and pfmdr1 86Y on the clinical efficacy of AQ and
CQ in southern Sudan, an area where CQ efficacy is still at
high levels.
We analyzed samples collected during a clinical trial of
efficacy of antimalarial agents in southern Sudan between
June and December 2001.The study was reviewed and approved
by the Ethical Committee of Me ´decins sans Frontie `res-
Holland (Amsterdam, The Netherlands). Local authorities
and the Sudanese People’s Democratic Front/counterpart
agreed with the study and helped to notify the population.
Blood collected by finger prick (50 L) was spotted onto filter
paper, air-dried, and stored in plastic bags with silica gel at
ambient temperature. Parasite genomic material was pre-
pared using the methanol procedure described elsewhere.
23
To detect a single base change at codon 76 of pfcrt and codon
86 of pfmdr1, we used the polymerase chain reaction
(PCR)−restriction enzyme protocol described in detail by
Professor Christopher Plowe (University of Maryland, Balti-
more, MD; Web site: http://medschool.umaryland.edu/cvd/
2002_pcr_asra.htm).
The detailed clinical results of CQ and AQ efficacy in
Sudan have been presented elsewhere.
24 Briefly, 104 and 101
patients were treated with CQ (10 mg/kg on day 0, 10 mg/kg
on day 1, and 5 mg/kg on day 2) and AQ (10 mg/kg on day 0,
10 mg/kg on day 1, and 5 mg/kg on day 2), respectively. Of
these, 14 (13.5%) of 104 and 7 (6.9%) of 101 had positive
parasitemias within 14 days after treatment and were scored
as CQ resistant and AQ resistant, respectively: these are para-
sitologic failures. Those whose blood samples were negative
14 days after treatment were scored as an adequate parasito-
logic response or harboring sensitive isolates. To test whether
polymorphisms in pfcrt and pfmdr1 are associated with the
CQ and AQ resistance response, we genotyped pfcrt at codon
76 and pfmdr1 at codon 86 in isolates from four groups of
patients: those showing an adequate parasitologic response to
CQ (n  28) and AQ (n  39), and those who had P. falci-
parum parasites in their blood within 14 days after treatment
with CQ (n  13) and AQ (n  6). All of these isolates were
collected on the day of admission into the study before treat-
ment was given.
The pfcrt and pfmdr1 genes were successfully amplified in
all isolates except for one from the AQ-resistant group (for
pfcrt) and two from the CQ-sensitive group (for pfmdr1). The
analysis of pfcrt showed that 93% (26 of 28) of the isolates
from patients treated with CQ with an adequate parasitologic
response were wild type (pfcrt 76K) and all 13 CQ-resistant
isolates carried the mutant allele (pfcrt 76T). The same trend
was observed in patients treated with AQ: 85% (33 of 39)
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184were wild type and 100% (5 of 5) carried the mutant allele
(pfcrt 76T) in the sensitive and resistant groups, respectively
(Table 1). The analysis of pfmdr1 showed that 92% (24 of 26)
of the CQ-sensitive isolates, as well as 92% (36/39) of the
AQ-sensitive isolates, were wild type (pfmdr1 86N). In con-
trast, the pfmdr1 86Y mutant allele was only found in 62%
(8 of 13) and 50% (3 of 6) of the isolates that failed to respond
to CQ and AQ, respectively (Table 2). When pfcrt and
pfmdr1 were analyzed together, more than 80% of the CQ-
and AQ-sensitive isolates carried the wild type pfcrt 76K-
pfmdr1 86N genotype (Figure 1). However, the combina-
tion of mutant genotypes pfcrt 76T-pfmdr1 86Y was observed
only in approximately 60% of both AQ- and CQ-resistant
isolates.
This is the first report of the assessment of the impact of
pfcrt markers on in vivo efficacy of AQ. Our data clearly
demonstrate that the pfcrt allele at codon 76, the most com-
mon marker for CQ resistance,
11−14 is also associated with
AQ resistance in vivo. Both CQ and AQ are 4-amino-
quinoline agents, and several reports
21,22 have shown that
these two drugs act in a similar manner against P. falciparum
by inhibiting the polymerization of heme, the toxic by-
product of hemoglobin degradation. It has been suggested
that AQ is more potent than CQ because of a higher accu-
mulation of AQ in the digestive vacuole of the parasite.
21,22,25
Therefore, since their chemical structures and their mode of
action are similar, one would expect that the selection of CQ
resistance would impact on the efficacy of AQ. As a conse-
quence, selection of markers for CQ resistance would have a
bearing on AQ resistance; this is what our data clearly
show. Overall, CQ and AQ both retain excellent efficacy
in our study site, and under these circumstances, the pfcrt
mutant could be used as a predictor of both CQ and AQ
resistance.
Recently, transfection studies of pfcrt have shown that iso-
lates expressing the mutant pfcrt 76T allele retain sensitivity
to AQ while showing a reduced susceptibility to monodes-
ethylamodiaquine (MDAQ), the active metabolite of AQ.
13
Therefore, the association between the mutant allele pfcrt
76T and AQ resistance we have found in vivo may reflect an
association of this allele with the active metabolite MDAQ.
The pfmdr1 86Y allele is not as strongly associated with
resistance as pfcrt76T. Indeed, we have found that only 62%
of the CQ-resistant isolates and 50% of the AQ-resistant iso-
lates harbor the mutant pfmdr1 86Y allele. The lack of asso-
ciation between this allele and CQ resistance has been re-
ported in different malaria-endemic areas.
15,19,20 We have
confirmed these observations in southern Sudan with CQ and
also report the lack of association of this marker with AQ
resistance.
In conclusion, our study shows that the mutant pfcrt 76T
allele is correlated with CQ resistance as previously re-
ported.
11,12 We also provide evidence that the selection of this
allele could explain, at least partly, the cross-resistance ob-
served between CQ and AQ in vivo. However, this study was
carried out in an area where CQ is still very effective. There-
fore, it remains to be seen if this pattern will also be observed
in the many areas of Africa where CQ resistance is already at
high levels.
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TABLE 1
Allelic polymorphisms of the pfcrt gene at codon 76 in samples collected before chloroquine and amodiaquine treatments*









pfcrt 76K (wild type) 26/28 (93%) 0 33/39 (85%) 0
pfcrt 76T (mutant) 2/28 (7%) 13/13 (100%) 6/39 (15%) 5/5 (100%)
* pfcrt  Plasmodium falciparum chloroquine resistance transporter (gene).
TABLE 2
Allelic polymorphisms of the pfmdr1 gene at codon 86 in samples collected before chloroquine and amodiaquine treatments*









pfmdr1 N86 (wild type) 24/26 (92%) 5/13 (38%) 36/39 (92%) 3/6 (50.00%)
pfmdr1 Y86 (mutant) 2/26 (8%) 8/13 (62%) 3/39 (8%) 3/6 (50.00%)
* pfmdr  Plasmodium falciparum multiple drug-resistance (gene).
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